<DOC>
	<DOCNO>NCT01962246</DOCNO>
	<brief_summary>Stage I：preoperative therapy - Capecitabine plus oxaliplatin concurrent radiotherapy superior surgery alone ; Stage II : Perioperative therapy - Perioperative Capecitabine plus oxaliplatin Concurrent radiotherapy superior adjuvant Capecitabine plus oxaliplatin alone ; - A regimen Capecitabine plus oxaliplatin ( XELOX ) improve survival among patient incurable locally advanced metastatic adenocarcinoma stomach gastroesophageal cancer . The investigator assess whether addition perioperative regimen XELOX regimen concurrent radiotherapy adjuvant alone improve R0 resection rate survival among patient curable locally advanced adenocarcinoma stomach gastroesophageal cancer</brief_summary>
	<brief_title>Preoperative Concurrent Chemoradiotherapy Potentially Resectable Adenocarcinoma Esophagogastric Junction</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Disease must clinically limited esophagogastric junction , define TypeⅡ TypeⅢ ( From endoscopic point view accord AEG criterion ) 2 . Histologically confirm primary adenocarcinoma 3 . T24 N03 M0 . T1 tumor eligible T1N13M0， 4 . ECOG performance status ≦2 AEG define described tumor center within 5cm proximal distal anatomical cardia . The classification AEG type I , type II type III AEG type I : adenocarcinoma distal esophagus , usually arise area specialize intestinal metaplasia esophagus , Barrett 's esophagus , may infiltrate esophagogastric junction ; AEG type II : true carcinoma cardia , arise cardia epithelium short segment intestinal metaplasia esophagogastric junction ; AEG type III : subcardial gastric carcinoma , infiltrate esophagogastric junction distal esophagus . 1 . Tis ( insitu carcinoma ) tumor determine TIN0 follow endoscopy , endoscopic ultrasound CT scanning . 2 . Patients primary carcinomas esophagus . 3 . Prior chest upper abdomen radiotherapy , prior systemic chemotherapy within past 5 year , prior esophageal gastric surgery . 4 . Patients evidence metastatic disease eligible . 5 . Patients history seizure disorder receive phenytoin , phenobarbital , antiepileptic medication . 6 . Patients fully comprehend therapeutic implication protocol comply requirement . 7 . Patients medical psychiatric condition disease , investigator 's judgment , would make patient inappropriate entry study . 8 . History hypersensitivity fluoropyrimidines , capecitabine , oxaliplatin ingredient product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Preoperative Concurrent Chemoradiotherapy</keyword>
	<keyword>Gastroesophageal Junction Adenocarcinoma</keyword>
</DOC>